readthroughSign in
Jul 2, 2026Financing7 fact check notes

Elicio prices $15 million registered direct stock offering

Elicio Therapeutics will sell 4,380,313 shares at $3.43 each to fund a planned Phase 1 trial combining ELI-002 7P with checkpoint or RAS inhibitors in metastatic pancreatic cancer.

The offering priced at $3.43 per share, with a placement agents' fee of $0.24 per share and proceeds to Elicio before expenses of $3.19 per share.1

Net proceeds after fees and expenses are estimated at approximately $13.6 million.1 Closing is expected on or about July 6, 2026, subject to customary closing conditions.2 Titan Partners, a division of American Capital Partners, is acting as lead placement agent, with B. Riley Securities, Inc. serving as co-placement agent.2

The company said it is refining its Phase 3 strategy toward that R0 population, subject to financing, and separately plans a Phase 1 study combining ELI-002 7P with an anti-PD-1 inhibitor and/or RAS inhibitor in metastatic disease.

Regarding the underlying shelf registration, the two filings give slightly different amendment histories. Elicio's stock trades on Nasdaq under the symbol ELTX.

Fact check notes

  • Checker's noteThe entry incorrectly attributes a specific registration-statement filing/amendment history ('filed Feb 27, 2026, as amended March 12, 2026, declared effective March 16, 2026') to the 424B5 prospectus supplement; that exact language actually appears in the 8-K's press release exhibit (Ex-99.1), not in the 424B5 text provided. The entry thus misidentifies the source and mischaracterizes the discrepancy as being between the two filings rather than within the 8-K itself.
  • Sentence removedElicio Therapeutics, Inc. (Nasdaq: ELTX) said on July 1, 2026 that it had entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering.copied source wording
  • Sentence removedThe offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents' fees and other offering expenses.copied source wording
  • Sentence removedElicio said it plans to use the money, along with existing cash, to primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and Elicio's pipeline and platform, as well as for working capital and general corporate purposes.copied source wording
  • Sentence removedThe offering follows Elicio's June 2026 disclosure that its Phase 2 AMPLIFY-7P trial did not meet its pre-specified primary disease-free survival endpoint in the intent-to-treat population, though post-hoc landmark analyses showed early treatment benefit and a stronger treatment effect in the R0 resected patient population.copied source wording
  • Sentence removedThe prospectus supplement states the Form S-3 registration statement, file number 333-293861, was filed with the SEC and later notes it was declared effective March 16, 2026, referencing amendments on February 27, 2026, as amended on March 12, 2026.contradicted: The language attributed to 'the prospectus supplement' (filed Feb 27, 2026, amended Mar 12, 2026, effective Mar 16, 2026) does not appear in the 424B5 text provided; it actually matches the press release exhibit within the 8-K (Ex-99.1), not the prospectus supplement. The entry misattributes which document contains which amendment history, and the discrepancy is actually between two parts of the same 8-K filing, not between the 424B5 and the 8-K as claimed.
  • Sentence removedThe 8-K, however, lists an additional amendment date, stating the registration statement was filed with the Securities and Exchange Commission on February 27, 2026, as amended on March 2, 2026 and further amended on March 12, 2026, and declared effective by the Commission on March 16, 2026.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.